NASDAQ:MGNX - MacroGenics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$21.75 +0.41 (+1.92 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$21.75
Today's Range$21.2150 - $21.85
52-Week Range$14.36 - $32.74
Volume192,708 shs
Average Volume295,361 shs
Market Capitalization$917.89 million
P/E Ratio-40.28
Dividend YieldN/A
Beta2.47

About MacroGenics (NASDAQ:MGNX)

MacroGenics logoMacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Debt-to-Equity RatioN/A
Current Ratio5.43
Quick Ratio5.43

Price-To-Earnings

Trailing P/E Ratio-40.28
Forward P/E Ratio-4.55
P/E GrowthN/A

Sales & Book Value

Annual Sales$157.74 million
Price / Sales5.82
Cash FlowN/A
Price / CashN/A
Book Value$5.86 per share
Price / Book3.71

Profitability

EPS (Most Recent Fiscal Year)($0.54)
Net Income$-19,620,000.00
Net Margins-19.64%
Return on Equity-13.03%
Return on Assets-10.36%

Miscellaneous

Employees330
Outstanding Shares42,200,000

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics (NASDAQ:MGNX) issued its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported $2.80 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.58 by $0.22. The biopharmaceutical company had revenue of $152.36 million for the quarter, compared to the consensus estimate of $152.59 million. MacroGenics had a negative return on equity of 13.03% and a negative net margin of 19.64%. View MacroGenics' Earnings History.

What price target have analysts set for MGNX?

10 Wall Street analysts have issued twelve-month price objectives for MacroGenics' shares. Their predictions range from $22.00 to $44.00. On average, they anticipate MacroGenics' stock price to reach $31.2857 in the next twelve months. View Analyst Ratings for MacroGenics.

Are investors shorting MacroGenics?

MacroGenics saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 3,055,741 shares, a decrease of 24.3% from the March 30th total of 4,034,237 shares. Based on an average trading volume of 405,524 shares, the days-to-cover ratio is currently 7.5 days. Currently, 9.4% of the company's stock are sold short.

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 66)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 51)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 64)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 45)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 56)

Has MacroGenics been receiving favorable news coverage?

Media coverage about MGNX stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. MacroGenics earned a media sentiment score of 0.15 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.71 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include OppenheimerFunds Inc. (9.36%), BlackRock Inc. (6.32%), Wasatch Advisors Inc. (2.42%), Millennium Management LLC (2.13%), Pinnacle Associates Ltd. (1.87%) and Hood River Capital Management LLC (1.54%). Company insiders that own MacroGenics stock include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Institutional Ownership Trends for MacroGenics.

Which institutional investors are selling MacroGenics stock?

MGNX stock was sold by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Prosight Management LP, DAFNA Capital Management LLC, Pinnacle Associates Ltd., Wasatch Advisors Inc., Sphera Funds Management LTD. and Legal & General Group Plc. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, James Karrels, Jon Marc Wigginton and Lynn Cilinski. View Insider Buying and Selling for MacroGenics.

Which institutional investors are buying MacroGenics stock?

MGNX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Victory Capital Management Inc., CVI Holdings LLC, Spark Investment Management LLC, Rock Springs Capital Management LP, Landscape Capital Management L.L.C., Citadel Advisors LLC and Trexquant Investment LP. View Insider Buying and Selling for MacroGenics.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $21.75.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $917.89 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (MGNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MacroGenics (NASDAQ:MGNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for MacroGenics in the last 12 months. Their average twelve-month price target is $31.2857, suggesting that the stock has a possible upside of 43.84%. The high price target for MGNX is $44.00 and the low price target for MGNX is $22.00. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.822.82
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.2857$31.8571$31.8889$31.3333
Price Target Upside: 43.84% upside41.09% upside37.27% upside71.69% upside

MacroGenics (NASDAQ:MGNX) Consensus Price Target History

Price Target History for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018WedbushReiterated RatingOutperform$44.00HighView Rating Details
5/8/2018HC WainwrightSet Price TargetBuy$34.00HighView Rating Details
4/6/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$18.00 ➝ $26.00MediumView Rating Details
1/24/2018CowenReiterated RatingBuyLowView Rating Details
1/23/2018SunTrust BanksReiterated RatingBuy$31.00HighView Rating Details
1/23/2018BTIG ResearchReiterated RatingBuy$28.00HighView Rating Details
12/11/2017Raymond JamesReiterated RatingBuyMediumView Rating Details
11/10/2017CitigroupBoost Price TargetNeutral$18.00 ➝ $22.00N/AView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$34.00HighView Rating Details
3/1/2017InstinetInitiated CoverageBuy ➝ Buy$41.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/AView Rating Details
6/14/2016OppenheimerReiterated RatingBuyN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

MacroGenics (NASDAQ:MGNX) Earnings History and Estimates Chart

Earnings by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ:MGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($4.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.13)($1.02)($1.08)
Q2 20182($1.24)($1.21)($1.23)
Q3 20183($1.35)($1.10)($1.22)
Q4 20183($1.39)($0.98)($1.19)

MacroGenics (NASDAQ MGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018Q1 2018($1.08)($1.34)$7.46 million$4.70 millionViewN/AView Earnings Details
2/27/2018Q4 2017$2.58$2.80$152.59 million$152.36 millionViewN/AView Earnings Details
11/8/2017Q3 2017($1.09)($1.28)$5.50 million$1.70 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.05)($1.14)$15.82 million$1.70 millionViewListenView Earnings Details
5/3/2017Q1 2017($0.99)($1.08)$5.88 million$2.06 millionViewListenView Earnings Details
2/28/2017Q416($0.86)($1.00)$10.65 million$5.00 millionViewListenView Earnings Details
11/2/2016Q316($0.80)($0.97)$12.45 million$3.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.02)$1.12$27.22 million$80.67 millionViewN/AView Earnings Details
5/4/2016Q1($0.67)($0.88)$10.95 million$2.85 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.56)($0.89)$12.36 million$8.18 millionViewN/AView Earnings Details
11/4/2015Q3 2015($0.21)($0.46)$22.95 million$14.68 millionViewN/AView Earnings Details
8/5/2015Q2($0.44)($0.71)$13.88 million$6.72 millionViewN/AView Earnings Details
5/6/2015Q1 2015$0.87($0.58)$58.29 million$71.28 millionViewN/AView Earnings Details
3/3/2015Q4 2014($0.36)($0.69)$12.41 million$5.48 millionViewN/AView Earnings Details
11/11/2014Q3 2014($0.42)($0.14)$9.43 million$18.38 millionViewListenView Earnings Details
8/5/2014Q2 2014($0.29)($0.44)$11.22 million$9.22 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.09)($0.12)$18.00 million$14.72 millionViewN/AView Earnings Details
11/12/2013$0.15$0.01$19.67 million$20.23 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

MacroGenics (NASDAQ:MGNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MacroGenics (NASDAQ MGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.82%
Institutional Ownership Percentage: 79.90%
Insider Trading History for MacroGenics (NASDAQ:MGNX)
Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

MacroGenics (NASDAQ MGNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2018Eric Blasius RisserSVPSell1,000$31.08$31,080.0010,100View SEC Filing  
3/5/2018James KarrelsCFOSell5,000$31.00$155,000.00View SEC Filing  
3/2/2018Eric Blasius RisserSVPSell4,000$30.00$120,000.0013,100View SEC Filing  
2/28/2018Eric Blasius RisserSVPSell1,000$25.01$25,010.00View SEC Filing  
2/28/2018Lynn CilinskiVPSell23,967$25.01$599,414.67View SEC Filing  
1/24/2018Eric Blasius RisserSVPSell3,000$22.50$67,500.0012,100View SEC Filing  
1/17/2018Jon Marc WiggintonSVPSell5,000$20.00$100,000.00View SEC Filing  
11/21/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.0035,000View SEC Filing  
10/25/2017Jon Marc WiggintonSVPSell10,000$20.00$200,000.0040,000View SEC Filing  
6/5/2017Jon Marc WiggintonSVPSell5,000$20.00$100,000.0035,000View SEC Filing  
4/19/2017Jon Marc WiggintonSVPSell15,000$20.00$300,000.0045,000View SEC Filing  
10/3/2016Jon Marc WiggintonCMOSell10,000$29.34$293,400.0010,000View SEC Filing  
10/3/2016Lynn CilinskiVPSell6,231$29.28$182,443.688,154View SEC Filing  
8/1/2016Jon Marc WiggintonSVPSell20,000$30.78$615,600.0020,000View SEC Filing  
7/1/2016Jon Marc WiggintonCMOSell5,000$27.22$136,100.005,000View SEC Filing  
7/1/2016Lynn CilinskiVPSell8,922$27.22$242,856.8410,845View SEC Filing  
5/27/2016Lynn CilinskiVPSell5,000$25.00$125,000.006,923View SEC Filing  
3/3/2016Paulo F CostaDirectorBuy10,000$17.20$172,000.0059,435View SEC Filing  
1/4/2016Jon Marc WiggintonSVPSell10,000$29.64$296,400.00View SEC Filing  
11/23/2015Lynn CilinskiVPSell6,921$35.00$242,235.001,923View SEC Filing  
11/16/2015Ezio BonviniVPSell3,117$31.44$97,998.4870,317View SEC Filing  
10/15/2015Ezio BonviniVPSell6,233$25.21$157,133.9373,434View SEC Filing  
10/1/2015Jon Marc WiggintonSVPSell5,000$21.11$105,550.00View SEC Filing  
7/10/2015Ezio BonviniVPSell2,400$38.09$91,416.00View SEC Filing  
7/1/2015Jon Marc WiggintonSVPSell5,000$37.15$185,750.00View SEC Filing  
7/1/2015Lynn CilinskiVPSell6,921$37.15$257,115.15View SEC Filing  
6/30/2015Ezio BonviniVPSell6,497$38.07$247,340.79View SEC Filing  
6/24/2015Ezio BonviniVPSell6,097$38.08$232,173.76View SEC Filing  
6/23/2015Ezio BonviniVPSell13,054$38.14$497,879.56View SEC Filing  
6/15/2015Ezio BonviniVPSell6,233$34.01$211,984.33View SEC Filing  
5/15/2015Ezio BonviniVPSell6,233$30.24$188,485.92View SEC Filing  
4/15/2015Ezio BonviniVPSell6,233$33.98$211,797.34View SEC Filing  
2/2/2015Jon Marc WiggintonSVPSell5,000$31.04$155,200.00View SEC Filing  
12/22/2014Kathryn E SteinSVPSell10,946$37.00$405,002.00View SEC Filing  
12/18/2014Eric Blasius RisserVPSell10,000$33.50$335,000.00View SEC Filing  
12/18/2014Kathryn E SteinSVPSell10,946$33.00$361,218.00View SEC Filing  
11/24/2014Eric Blasius RisserVPSell10,000$27.75$277,500.00View SEC Filing  
11/21/2014Kathryn E SteinVPSell10,946$27.00$295,542.00View SEC Filing  
11/17/2014Kathryn E SteinVPSell25,301$23.30$589,513.30View SEC Filing  
11/13/2014Eric Blasius RisserVPSell25,000$23.80$595,000.00View SEC Filing  
10/1/2014Jon Marc WiggintonVPSell5,000$20.48$102,400.00View SEC Filing  
9/2/2014Eric Blasius RisserVPSell8,316$20.89$173,721.24View SEC Filing  
8/18/2014Jon Marc WiggintonVPSell5,000$20.52$102,600.00View SEC Filing  
6/30/2014Eric Blasius RisserVPSell8,000$21.84$174,720.00View SEC Filing  
5/29/2014Kathryn E SteinVPSell10,946$19.75$216,183.50View SEC Filing  
2/18/2014Edward HurwitzDirectorSell308,513$36.50$11,260,724.50View SEC Filing  
10/16/2013Kenneth GalbraithDirectorBuy46,875$16.00$750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

MacroGenics (NASDAQ MGNX) News Headlines

Source:
DateHeadline
MacroGenics (MGNX) Receives Consensus Recommendation of "Buy" from AnalystsMacroGenics (MGNX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 20 at 3:52 PM
MacroGenics (MGNX) Upgraded to Hold at BidaskClubMacroGenics (MGNX) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - May 19 at 11:03 AM
MacroGenics (MGNX) Cut to "Sell" at BidaskClubMacroGenics (MGNX) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - May 11 at 7:53 PM
Leerink Swann Equities Analysts Reduce Earnings Estimates for MacroGenics (MGNX)Leerink Swann Equities Analysts Reduce Earnings Estimates for MacroGenics (MGNX)
www.americanbankingnews.com - May 10 at 7:55 AM
SunTrust Banks Research Analysts Decrease Earnings Estimates for MacroGenics (MGNX)SunTrust Banks Research Analysts Decrease Earnings Estimates for MacroGenics (MGNX)
www.americanbankingnews.com - May 10 at 7:04 AM
Wedbush Analysts Increase Earnings Estimates for MacroGenics (MGNX)Wedbush Analysts Increase Earnings Estimates for MacroGenics (MGNX)
www.americanbankingnews.com - May 10 at 7:04 AM
MacroGenics (MGNX) Rating Lowered to Hold at Zacks Investment ResearchMacroGenics (MGNX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 8:52 AM
MacroGenics (MGNX) "Outperform" Rating Reaffirmed at WedbushMacroGenics' (MGNX) "Outperform" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - May 8 at 3:45 PM
HC Wainwright Analysts Give MacroGenics (MGNX) a $34.00 Price TargetHC Wainwright Analysts Give MacroGenics (MGNX) a $34.00 Price Target
www.americanbankingnews.com - May 8 at 2:28 PM
MacroGenics (MGNX) Issues Quarterly  Earnings Results, Misses Estimates By $0.26 EPSMacroGenics (MGNX) Issues Quarterly Earnings Results, Misses Estimates By $0.26 EPS
www.americanbankingnews.com - May 8 at 11:32 AM
BRIEF-MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34BRIEF-MacroGenics Posts Qtrly Net Loss Per Common Share Of $1.34
www.reuters.com - May 8 at 9:13 AM
MacroGenics (MGNX) CEO Scott Koenig on Q1 2018 Results - Earnings Call TranscriptMacroGenics' (MGNX) CEO Scott Koenig on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 9:13 AM
MacroGenics to Present at Deutsche Bank Health Care ConferenceMacroGenics to Present at Deutsche Bank Health Care Conference
feeds.benzinga.com - May 7 at 7:09 PM
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial ResultsMacroGenics Provides Update on Corporate Progress and 1st Quarter 2018 Financial Results
finance.yahoo.com - May 7 at 4:47 PM
MacroGenics: 1Q Earnings SnapshotMacroGenics: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 4:47 PM
MacroGenics (MGNX) Expected to Post Quarterly Sales of $7.46 MillionMacroGenics (MGNX) Expected to Post Quarterly Sales of $7.46 Million
www.americanbankingnews.com - May 6 at 2:56 AM
MacroGenics (MGNX) Expected to Announce Earnings of -$1.08 Per ShareMacroGenics (MGNX) Expected to Announce Earnings of -$1.08 Per Share
www.americanbankingnews.com - May 4 at 3:53 PM
MacroGenics (MGNX) Upgraded at ValuEngineMacroGenics (MGNX) Upgraded at ValuEngine
www.americanbankingnews.com - May 3 at 12:10 AM
MacroGenics (MGNX) Upgraded to "Buy" at Zacks Investment ResearchMacroGenics (MGNX) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 11:28 AM
MacroGenics (MGNX) Sees Significant Decline in Short InterestMacroGenics (MGNX) Sees Significant Decline in Short Interest
www.americanbankingnews.com - April 29 at 2:44 AM
MacroGenics (MGNX) Given Consensus Recommendation of "Hold" by BrokeragesMacroGenics (MGNX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 25 at 3:32 PM
MacroGenics (MGNX) to Release Quarterly Earnings on TuesdayMacroGenics (MGNX) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 24 at 7:56 AM
MacroGenics (MGNX) Cut to "Sell" at ValuEngineMacroGenics (MGNX) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 23 at 11:18 PM
MacroGenics (MGNX) Cut to Sell at Zacks Investment ResearchMacroGenics (MGNX) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - April 19 at 5:18 PM
$7.46 Million in Sales Expected for MacroGenics Inc (MGNX) This Quarter$7.46 Million in Sales Expected for MacroGenics Inc (MGNX) This Quarter
www.americanbankingnews.com - April 19 at 3:04 AM
MacroGenics (MGNX) Upgraded to "Hold" at Zacks Investment ResearchMacroGenics (MGNX) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 9:49 PM
-$1.08 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter-$1.08 Earnings Per Share Expected for MacroGenics Inc (MGNX) This Quarter
www.americanbankingnews.com - April 17 at 1:17 PM
MacroGenics (MGNX) Downgraded by BidaskClubMacroGenics (MGNX) Downgraded by BidaskClub
www.americanbankingnews.com - April 14 at 10:19 PM
MacroGenics (MGNX) Downgraded by ValuEngineMacroGenics (MGNX) Downgraded by ValuEngine
www.americanbankingnews.com - April 13 at 1:35 PM
MacroGenics (MGNX) Stock Rating Lowered by Zacks Investment ResearchMacroGenics (MGNX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 13 at 1:00 PM
Investor Expectations to Drive Momentum within Companhia de saneamento Basico Do Estado De Sao Paulo ...Investor Expectations to Drive Momentum within Companhia de saneamento Basico Do Estado De Sao Paulo ...
globenewswire.com - April 13 at 9:29 AM
Leerink Swann Reaffirms "Outperform" Rating for MacroGenics (MGNX)Leerink Swann Reaffirms "Outperform" Rating for MacroGenics (MGNX)
www.americanbankingnews.com - April 10 at 8:27 AM
MacroGenics (MGNX) Upgraded at Zacks Investment ResearchMacroGenics (MGNX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 7:17 PM
MacroGenics (MGNX) Cut to "Hold" at BidaskClubMacroGenics (MGNX) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
MacroGenics (MGNX) Stock Rating Reaffirmed by CowenMacroGenics (MGNX) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 4 at 9:36 PM
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to ...MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to ...
globenewswire.com - April 3 at 9:25 AM
MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesMacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - April 2 at 4:43 PM
MacroGenics Inc (MGNX) Receives Average Recommendation of "Buy" from AnalystsMacroGenics Inc (MGNX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 31 at 3:50 PM
Zacks: Brokerages Expect MacroGenics Inc (MGNX) Will Announce Earnings of -$1.10 Per ShareZacks: Brokerages Expect MacroGenics Inc (MGNX) Will Announce Earnings of -$1.10 Per Share
www.americanbankingnews.com - March 31 at 3:14 PM
MacroGenics (MGNX) Stock Rating Upgraded by Zacks Investment ResearchMacroGenics (MGNX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:26 AM
MacroGenics (MGNX) Upgraded at TheStreetMacroGenics (MGNX) Upgraded at TheStreet
www.americanbankingnews.com - March 29 at 11:11 AM
What Should You Know About MacroGenics Inc’s (NASDAQ:MGNX) Growth?What Should You Know About MacroGenics Inc’s (NASDAQ:MGNX) Growth?
finance.yahoo.com - March 28 at 4:38 PM
MacroGenics Inc. (MGNX) Is Falling After Offering AnnouncementMacroGenics Inc. (MGNX) Is Falling After Offering Announcement
www.nasdaq.com - March 28 at 9:09 AM
Macrogenics (MGNX) Prices 4.5M Common Stock Offering at $21.25/ShareMacrogenics (MGNX) Prices 4.5M Common Stock Offering at $21.25/Share
www.streetinsider.com - March 28 at 9:09 AM
MacroGenics Announces Pricing of Public Offering of Common StockMacroGenics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 28 at 9:09 AM
MacroGenics (MGNX) Rating Reiterated by SunTrust BanksMacroGenics (MGNX) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 26 at 6:30 PM
MacroGenics Announces Proposed Public Offering of Common StockMacroGenics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 26 at 4:49 PM
 Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $7.46 Million Brokerages Expect MacroGenics Inc (MGNX) Will Post Quarterly Sales of $7.46 Million
www.americanbankingnews.com - March 16 at 4:40 AM
Eric Blasius Risser Sells 1,000 Shares of MacroGenics Inc (MGNX) StockEric Blasius Risser Sells 1,000 Shares of MacroGenics Inc (MGNX) Stock
www.americanbankingnews.com - March 14 at 8:29 PM
MacroGenics (MGNX) Price Target Increased to $26.00 by Analysts at Morgan StanleyMacroGenics (MGNX) Price Target Increased to $26.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - March 14 at 11:44 AM

SEC Filings

MacroGenics (NASDAQ:MGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

MacroGenics (NASDAQ:MGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

MacroGenics (NASDAQ MGNX) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.